Management of early pregnancy loss with mifepristone and misoprostol: clinical predictors of treatment success from a randomized trial
S Sonalkar, N Koelper, MD Creinin, JM Atrio… - American journal of …, 2020 - Elsevier
Background Early pregnancy loss is a common event in the first trimester, occurring in 15%–
20% of confirmed pregnancies. A common evidence-based medical regimen for early
pregnancy loss uses misoprostol, a prostaglandin E1 analog, with a dosage of 800 μg, self-
administered vaginally. The clinical utility of this regimen is limited by suboptimal
effectiveness in patients with a closed cervical os, with 29% of patients experiencing early
pregnancy loss requiring a second dose after 3 days and 16% of patients eventually …
20% of confirmed pregnancies. A common evidence-based medical regimen for early
pregnancy loss uses misoprostol, a prostaglandin E1 analog, with a dosage of 800 μg, self-
administered vaginally. The clinical utility of this regimen is limited by suboptimal
effectiveness in patients with a closed cervical os, with 29% of patients experiencing early
pregnancy loss requiring a second dose after 3 days and 16% of patients eventually …
以上显示的是最相近的搜索结果。 查看全部搜索结果